ATE253908T1 - Rhodamin 123 zusammensetzungen für behandlung von prostatakrebs - Google Patents

Rhodamin 123 zusammensetzungen für behandlung von prostatakrebs

Info

Publication number
ATE253908T1
ATE253908T1 AT96305836T AT96305836T ATE253908T1 AT E253908 T1 ATE253908 T1 AT E253908T1 AT 96305836 T AT96305836 T AT 96305836T AT 96305836 T AT96305836 T AT 96305836T AT E253908 T1 ATE253908 T1 AT E253908T1
Authority
AT
Austria
Prior art keywords
treatment
prostate cancer
solution
rhodamine
water
Prior art date
Application number
AT96305836T
Other languages
English (en)
Inventor
John Albert Arcadi
Original Assignee
Huntington Medical Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huntington Medical Res Inst filed Critical Huntington Medical Res Inst
Application granted granted Critical
Publication of ATE253908T1 publication Critical patent/ATE253908T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96305836T 1995-08-16 1996-08-08 Rhodamin 123 zusammensetzungen für behandlung von prostatakrebs ATE253908T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51600495A 1995-08-16 1995-08-16

Publications (1)

Publication Number Publication Date
ATE253908T1 true ATE253908T1 (de) 2003-11-15

Family

ID=24053711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96305836T ATE253908T1 (de) 1995-08-16 1996-08-08 Rhodamin 123 zusammensetzungen für behandlung von prostatakrebs

Country Status (8)

Country Link
US (1) US7008961B1 (de)
EP (1) EP0761216B1 (de)
JP (1) JPH09110724A (de)
AT (1) ATE253908T1 (de)
AU (1) AU6207196A (de)
BR (1) BR9603454A (de)
CA (1) CA2183015A1 (de)
DE (1) DE69630639T2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
WO2003020977A2 (en) * 2001-08-31 2003-03-13 The University Court Of The University Of Glasgow Nucleotide repeats assay
WO2006024491A1 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Methods and compositions for the treatment of cell proliferation
RU2354369C2 (ru) * 2007-03-16 2009-05-10 Михаил Владимирович Кутушов Применение родамина 6ж в качестве лекарственного средства для лечения злокачественных новообразований и амилоидозов
US20100144854A1 (en) * 2007-03-16 2010-06-10 Mikhail Kutushov Use of rhodamine 6g as a medicinal agent for treating malignant neoplasms and amiloidoses
US20120122966A1 (en) * 2009-04-14 2012-05-17 Mikhail Vladimirovich Kutushov Use of organic dyes as analgesic agents
US11474098B2 (en) 2017-12-22 2022-10-18 The Trustees Of Columbia University In The City Of New York Drug target for preventing pathologic calcium overload in cardiomyocytes and methods of screening for same
CN117677386A (zh) * 2021-07-23 2024-03-08 瓦伦塔有限责任公司 具有亲溶酶体和抗病毒活性的化合物
CN118121622A (zh) * 2024-01-29 2024-06-04 首都医科大学附属北京友谊医院 Se@SiO2-DTX在制备治疗前列腺癌或去势抵抗性前列腺癌产品中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260327A (en) * 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
US5189029A (en) * 1990-04-23 1993-02-23 Bo-Dekk Ventures, Ltd. Indacene compounds and methods for using the same
CA2075750C (en) 1991-08-13 1998-02-24 Lan Bo Chen Composition and method for treating cancer
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
AU6207196A (en) 1997-02-20
MX9603412A (es) 1997-07-31
US7008961B1 (en) 2006-03-07
BR9603454A (pt) 1998-05-12
CA2183015A1 (en) 1997-02-17
DE69630639T2 (de) 2004-09-16
EP0761216A1 (de) 1997-03-12
JPH09110724A (ja) 1997-04-28
EP0761216B1 (de) 2003-11-12
DE69630639D1 (de) 2003-12-18

Similar Documents

Publication Publication Date Title
EP0802782A4 (de) Prophylaktische und therapeutische behandlung von haupt sensibilisierung und -reizung
DE69215722D1 (de) Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
ES2035259T3 (es) Compuesto absorbente.
BRPI0011640B8 (pt) ácidos aldônicos de oligossacarídeo e seu uso tópico
KR960010010A (ko) 신규생리활성물질
DE3582439D1 (de) Mittel zur behandlung von herzerkrankungen.
DE69630639D1 (de) Rhodamin 123 Zusammensetzungen für Behandlung von Prostatakrebs
ES2033021T3 (es) Agente con efecto destructivo a tumores malignos, procedimiento para su obtencion y preparacion para la aplicacion en la terapia de enfermos de cancer.
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
DE69825887D1 (de) Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs
ATE421319T1 (de) Mit s-nitrosothiol angereicherte erythrocyten und deren verwendung
BE899809A (fr) Compositions pour usage cosmetique avec protection de la sante et du corps.
KR910005858A (ko) 지방산 요법
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
DE68912020D1 (de) N-2,3-Butadienyl-tri-aminoalkanderivate.
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
SE8102161L (sv) "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
RU97112272A (ru) Способ лечения острых воспалительных заболеваний внутренних половых органов у женщин
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
NO960347D0 (no) Anvendelse av benzydamid ved behandling av patologiske tilstander forårsaket av TNF
DE3569469D1 (en) Use of phytosterolglycosides for the preparation of medicaments for treatment of elevated 5(6)alpha-epoxycholesterol levels
KR900017599A (ko) 종양 치료용 약학 조성물
KR930702016A (ko) 골다공증 치료제
RU95102346A (ru) Способ лечения дисциркуляторной энцефалопатии

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties